Applied DNA Sciences announced that the New York State Department of Health approved the Company’s TR8 PGx pharmacogenomic testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and concierge physicians seeking to add PGx testing to their test menu. Applied DNA’s clinical laboratory subsidiary, Applied DNA Clinical Labs, is launching its PGx testing service to help guide healthcare providers to administer a wide range of medications relevant to cardiovascular, oncology, psychiatric, infectious disease, and pain management treatments based on a patient’s unique genetics. The service is available by prescription only and will initially target the patient population of New York State. The TR8 PGx test analyzes 120 genetic targets across more than 30 genes to inform a healthcare provider how a patient may respond to a wide range of medications used to treat a variety of conditions, such as cardiovascular, oncology, psychiatric, and pain management. The test is administered via a simple cheek swab.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APDN:
- Applied DNA Sciences price target lowered to $1.50 from $7 at H.C. Wainwright
- Applied DNA announces notice of allowance for U.S. patent covering Linea RNAP
- Applied DNA Sciences’ $12M Securities Offering and Agreement
- Applied DNA Sciences downgraded to Hold from Buy at Maxim
- Applied DNA Sciences announces presentation on use of Linea DNA